Genmab | GEN - Gross Profit On Sales

Stock Price
1,966.00
Daily Change
-21.50 -1.08%
Monthly
-9.23%
Yearly
41.95%
Q1 Forecast
1,920.90

Genmab reported DKK868M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
Amgen USD 6.48B 307M Sep/2025
argenx SE USD 1.02B 180.32M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Demant DKK 8.82B 277M Dec/2025
Exelixis USD 579.18M 30.39M Sep/2025
Fresenius Medical Care EUR 1.24B 27M Sep/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 868M 195M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
GN Store Nord DKK 2.5B 344M Dec/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Insmed USD 111.44M 33.36M Sep/2025
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.21B 186M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 2.46B 520M Dec/2024